BidaskClub Lowers Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to Hold

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Monday, July 24th.

Other equities research analysts also recently issued research reports about the stock. Royal Bank Of Canada restated an “outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Jefferies Group LLC restated a “buy” rating and issued a $148.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, June 30th. Citigroup Inc. boosted their target price on shares of Zimmer Biomet Holdings from $108.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, June 9th. Wells Fargo & Company restated a “market weight” rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $141.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings presently has an average rating of “Hold” and a consensus price target of $136.90.

Shares of Zimmer Biomet Holdings (ZBH) opened at 111.38 on Monday. The firm has a market capitalization of $22.52 billion, a PE ratio of 31.72 and a beta of 1.20. The firm’s 50 day moving average is $122.63 and its 200-day moving average is $121.15. Zimmer Biomet Holdings has a one year low of $95.63 and a one year high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same quarter in the prior year, the firm earned $2.02 EPS. The firm’s quarterly revenue was up 1.1% on a year-over-year basis. On average, equities research analysts predict that Zimmer Biomet Holdings will post $8.24 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “BidaskClub Lowers Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to Hold” was originally published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/bidaskclub-downgrades-zimmer-biomet-holdings-inc-nysezbh-to-hold-updated-updated-updated.html.

In other news, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. Insiders own 1.07% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Parkside Financial Bank & Trust raised its position in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Zimmer Biomet Holdings by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 167 shares during the last quarter. Parallel Advisors LLC raised its position in Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares during the last quarter. IHT Wealth Management LLC raised its position in Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares during the last quarter. Finally, BB&T Investment Services Inc. bought a new position in Zimmer Biomet Holdings during the second quarter valued at about $144,000. Institutional investors own 82.84% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply